Physician profile
Anthony Carlino
NPI 1649296310
$2,460.62
in general payments reported to CMS, 2019-2025
31 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $195 · 2021: $257 · 2022: $420 · 2023: $316 · 2024: $377 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $830.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $232.52 | 2019-2025 | |
| Exact Sciences Corporation | $162.51 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $162.39 | 2019-2023 | |
| Lilly USA, LLC | $124.49 | 2020-2025 | Zepbound, Jardiance |
| Amgen INC. | $113.70 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $109.85 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.02 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.80 | 2019-2023 | Jardiance, Spiriva |
| Dynavax Technologies Corporation | $62.33 | 2019-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $61.16 | 2022-2025 | Andexxa, Fasenra |
| Novartis Pharmaceuticals Corporation | $57.75 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $46.48 | 2022-2025 | Ultomiris |
| Xeris Pharmaceuticals, INC. | $38.79 | 2025 | Recorlev |
| Tactile Systems Technology INC | $38.29 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $29.26 | 2024 | Giapreza |
| Daiichi Sankyo INC. | $29.00 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $18.09 | 2022 | |
| Glaxosmithkline, LLC. | $17.00 | 2024 | Arexvy |
| Melinta Therapeutics, LLC | $15.04 | 2022 | |
| Genentech USA, INC. | $15.00 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.00 | 2024 | Horizant |
| Csl Behring | $14.44 | 2022 | |
| Chiesi USA, INC. | $14.43 | 2022 | |
| Eisai INC. | $13.80 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.79 | 2019 | |
| Almatica Pharma LLC | $13.64 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.23 | 2019 | |
| Shionogi INC | $13.18 | 2022 | |
| Nabriva Therapeutics, Plc | $12.40 | 2020 | |
| Amarin Pharma, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Carlino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.